Search Result

Results for "

gsk3+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (2) CDK (5) GSK-3 (37) HSV (1) Mitophagy (1) Phosphodiesterase (PDE) (1) PKC (4) Reference Standards (4) Tau Protein (1)
By Research Areas:	Cancer (15) Infection (2) Inflammation/Immunology (1) Metabolic Disease (13) Neurological Disease (23)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10580

GSK 3 Inhibitor IX 15+ Cited Publications 6-Bromoindirubin-3'-oxime; BIO; MLS 2052	GSK-3 CDK Apoptosis	Cancer
GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of *GSK-3α/β* and CDK1-cyclinB complex with IC₅₀s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.

HY-13867

Bisindolylmaleimide I 35+ Cited Publications GF109203X; Go 6850	PKC GSK-3	Metabolic Disease Cancer
Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC₅₀ of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a *GSK-3* inhibitor ^[3].

HY-14872

Tideglusib 5+ Cited Publications NP031112	GSK-3	Neurological Disease
Tideglusib (NP031112) is an irreversible *GSK-3* inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β ^WT (1 h preincubation) and GSK-3β ^C199A (1 h preincubation), respectively.

HY-12012

SB 216763 Maximum Cited Publications 43 Publications Verification	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 is potent, selective and ATP-competitive *GSK-3* inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

HY-13862

AZD1080 5 Publications Verification	GSK-3	Neurological Disease
AZD1080 is a potent and selective *GSK3* inhibitor. AZD1080 inhibits recombinant human *GSK3α* and *GSK3β* with pK_i (IC₅₀) of 8.2 (6.9 nM) and 7.5 (31 nM), respectively.

HY-15761

AZD2858 5+ Cited Publications	GSK-3	Neurological Disease
AZD2858 is a potent, orally active *GSK-3* inhibitor, with IC₅₀s of 0.9 and 5 nM for *GSK-3α* and *GSK-3β*, respectively, used in the research of fracture healing.

HY-13076

CHIR-98014 5+ Cited Publications	GSK-3	Metabolic Disease
CHIR-98014 is a potent, cell-permeable *GSK-3* inhibitor with IC₅₀s of 0.65 and 0.58 nM for *GSK-3α* and *GSK-3β*, respectively; it shows less potent activities against cdc2 and erk2.

HY-107531

A 1070722	GSK-3	Neurological Disease Cancer
A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .

HY-15356

BIO-acetoxime 2 Publications Verification BIA	GSK-3 Apoptosis HSV	Infection Neurological Disease Inflammation/Immunology
BIO-acetoxime (BIA) is a potent and selective *GSK-3* inhibitor, with IC₅₀s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.

HY-154851

GSK-3 inhibitor 3	GSK-3 CDK Tau Protein	Neurological Disease
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of *GSK-3, with IC₅₀s of 0.35 nM and 0.25 nM for GSK-3α* and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC₅₀ of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research .

HY-13867A

Bisindolylmaleimide I hydrochloride 35+ Cited Publications GF109203X hydrochloride; Go 6850 hydrochloride	PKC GSK-3	Metabolic Disease Cancer
Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC₅₀ of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a *GSK-3* inhibitor ^[3].

HY-153089

GSK3-IN-3 4 Publications Verification	GSK-3 Mitophagy	Neurological Disease
GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a *GSK-3* inhibitor with an IC₅₀ value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA ^[3].

HY-122026

PF-04802367 PF-367	GSK-3	Neurological Disease
PF-04802367 (PF-367) is a highly selective *GSK-3* inhibitor with an IC₅₀ of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and *GSK-3β) with IC₅₀* values of 10.0 and 9.0 nM in mobility shift assays, respectively .

HY-13973A

GSK-3 inhibitor 1 1 Publications Verification	GSK-3	Metabolic Disease
GSK-3 inhibitor 1 (compound core 3) is a *GSK-3* inhibitor that induces stem/progenitor cell self-renewal (e.g. induces stem/progenitor cell proliferation while maintaining the ability to differentiate into tissue cells in the progeny) .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of *GSK-3, CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-114903

(E/Z)-BIO-acetoxime gsk-3 Inhibitor X	GSK-3 CDK	Neurological Disease Metabolic Disease Cancer
(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective *GSK-3α/β* inhibitor, with an IC₅₀ of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC₅₀=2.4, 4.3, 63 μM) .

HY-107815

CHIR 98024	GSK-3	Neurological Disease
CHIR 98024 (Compound L) is a glycogen synthase kinase 3 (GSK3) inhibitor with an EC₅₀ of 0.2566 μM .

HY-Q48328

GSK3-IN-1	GSK-3	Metabolic Disease
GSK3-IN-1 (compound 11) is a *GSK-3* inhibitor with an IC₅₀ value of 12 μM. GSK3-IN-1 can be used in the research of diabetes .

HY-111055

BIP-135	GSK-3	Neurological Disease
BIP-135 is a potent and selective ATP-competitive *GSK-3* inhibitor, with IC₅₀s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect .

HY-112392

GSK-3 Inhibitor XIII	GSK-3	Cancer
GSK-3 Inhibitor XIII is a potent and ATP-competitive *GSK-3* inhibitor with a K_i of 24 nM .

HY-148329

GSK3-IN-2	GSK-3	Metabolic Disease
GSK3-IN-2 (compound 8) is a potent *GSK3* inhibitor .

HY-134557

GS87	GSK-3	Cancer
GS87 is a highly specific and potent *GSK3* inhibitor with IC₅₀s of 415nM and 521nM for GSK3α and GSK3β, respectively. GS87 induces differentiation of acute myeloid leukemia (AML) cell lines by effectively activating GSK3-dependent signaling components including MAPK signaling. GS87 modulates key GSK3 target proteins involved in cell proliferation and differentiation more effectively than Lithium and SB415285 (SB). GS87 has the potential for acting as a differentiation agent for non-promyelocytic AML research .

HY-W773779

GSK3-IN-9	GSK-3	Neurological Disease Metabolic Disease Cancer
GSK3-IN-9 (Compound 0713) is a selective glycogen synthase kinase 3 (GSK3) inhibitor. GSK3-IN-9 Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder .

HY-13867R

Bisindolylmaleimide I (Standard) GF109203X (Standard); Go 6850 (Standard)	PKC GSK-3 Reference Standards	Metabolic Disease Cancer
Bisindolylmaleimide I (Standard) is the analytical standard of Bisindolylmaleimide I. This product is intended for research and analytical applications. Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a GSK-3 inhibitor ^[3].

HY-128879

VP3.15	Phosphodiesterase (PDE) GSK-3	Neurological Disease
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) .

HY-126201

GSK-3 inhibitor 7	GSK-3	Neurological Disease
GSK-3 inhibitor 7 (compound 22) is a glycogen synthase kinase-3 (GSK-3) inhibitor. GSK-3 inhibitor 7 can be used in nervous system research .

HY-162722

GSK-3 inhibitor 6	GSK-3	Others
GSK-3 inhibitor 6 (2) is a CNS penetrated *GSK-3* inhibitor, with IC₅₀ values of 29 nM and 24 nM for GSK-3α and GSK-3β, respectively .

HY-117739

BRD1652	GSK-3	Neurological Disease
BRD1652 is a highly selective *GSK3* inhibitor. BRD1652 can be used in the study of emotion-related diseases .

HY-155989

GSK3-IN-4	GSK-3	Neurological Disease
GSK3-IN-4 (compound 0715) is a potent *GSK3* inhibitor. GSK3-IN-4 can be used for psychiatric disorder research .

HY-12074

Cazpaullone	GSK-3	Metabolic Disease
Cazpaullone is a glycogen synthase kinase-3 (GSK-3) inhibitor. Cazpaullone can activate pancreatic beta cell protection and replication. Cazpaullone can be used for the research of diabetes .

HY-124607

(R)-BRD3731	GSK-3	Neurological Disease
(R)-BRD3731 is a *GSK3* inhibitor extracted from patent US20160375006A1, compound example 273, has IC₅₀s of 1.05 and 6.7 μM for *GSK3β* and *GSK3α*, respectively .

HY-12012R

SB 216763 (Standard)	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 (Standard) is the analytical standard of SB 216763. This product is intended for research and analytical applications. SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC50s of 34.3 nM for both GSK-3α and GSK-3β.

HY-13867AR

Bisindolylmaleimide I hydrochloride (Standard) GF109203X hydrochloride (Standard); Go 6850 hydrochloride (Standard)	PKC GSK-3 Reference Standards	Metabolic Disease Cancer
Bisindolylmaleimide I (hydrochloride) (Standard) is the analytical standard of Bisindolylmaleimide I (hydrochloride). This product is intended for research and analytical applications. Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a GSK-3 inhibitor ^[3].

HY-10580R

GSK 3 Inhibitor IX (Standard) 6-Bromoindirubin-3'-oxime (Standard); BIO (Standard); MLS 2052 (Standard)	Reference Standards GSK-3 CDK Apoptosis	Cancer
GSK 3 Inhibitor IX (Standard) is the analytical standard of GSK 3 Inhibitor IX (HY-10580). This product is intended for research and analytical applications. GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC₅₀s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.

HY-116696

GSK3-IN-11	GSK-3	Infection Neurological Disease Metabolic Disease Cancer
GSK3-IN-11 is a Glycogen Synthase Kinase-3 (GSK-3) inhibitor with an IC₅₀ of 5010 nM .

HY-117198

CHIR-21208	GSK-3	Neurological Disease Metabolic Disease
CHIR-21208 is a highly selective glycogen synthase kinase-3 (GSK-3) inhibitor. CHIR-21208 is promising for research of neurodegenerative disorders like Alzheimer's disease and type 2 diabetes .

HY-107531R

A 1070722 (Standard)	Reference Standards GSK-3	Neurological Disease Cancer
A 1070722 (Standard) is the analytical standard of A 1070722 (HY-107531). This product is intended for research and analytical applications. A 1070722 is a potent and selective glycogen synthase K_inase 3 (GSK-3) inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

gsk3+inhibitor

Inhibitors & Agonists